English
  1. Home
  2. Stocks
  3. Pplpharma Share Price
  • Chart
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs

    • Piramal Pharma

    Mid Cap
    ₹150.3
    +0.45 (0.3%)
    18 May, 2024 11:22 BSE: 543635 NSE: PPLPHARMAISIN: INE0DK501011

    Start SIP in Piramal Pharma

    Start SIP

    Piramal Pharma Performance

    Day Range

    • Low 150
    • High 151
    ₹ 150

    52 Week Range

    • Low 70
    • High 167
    ₹ 150
    • Open Price151
    • Previous Close150
    • Volume147071

    Piramal Pharma Share Price

    • Over 1 Month +6.22%
    • Over 3 Month +11.75%
    • Over 6 Month +28.74%
    • Over 1 Year +112.59%

    Piramal Pharma Key Statistics

    P/E Ratio 1115.9
    PEG Ratio 10.2
    Market Cap Cr 19,885
    Price to Book Ratio 2.5
    EPS 3
    Dividend 0
    Relative Strength Index 56.94
    Money Flow Index 78.36
    MACD Signal 4.16
    Average True Range 6.27
    Piramal Pharma Financials
    IndicatorMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 1,5251,0249948461,055
    Operating Expenses Qtr Cr 1,136899908830965
    Operating Profit Qtr Cr 390126861790
    Depreciation Qtr Cr 5352515053
    Interest Qtr Cr 2817283434
    Tax Qtr Cr 901519-824
    Net Profit Qtr Cr 2737477-3342
    Sign Up to Know More
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 4,5923,784
    Operating Expenses Annual Cr 3,7723,346
    Operating Profit Annual in Cr 61898
    Depreciation Cr 205192
    Interest Annual Cr 107116
    Tax Annual Cr 11654
    Net Profit Annual Cr 39170
    Sign Up to Know More
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 35872
    Cash from Investing Activity Annual Cr -636-435
    Cash from Financing Annual Activity Cr 451290
    Net Cash Flow Annual Cr 174-73
    Sign Up to Know More
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 6,7125,262
    Fixed Assets Annual Cr 3,0223,018
    Total Non Current Assets Annual Cr 6,2595,694
    Total Current Assets Annual Cr 3,2922,349
    Total Assets Annual Cr 9,5518,042
    Sign Up to Know More
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 5144
    ROE Annual % 61
    ROCE Annual % 84
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 1913
    Sign Up to Know More
    IndicatorMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 2,5521,9591,9111,7492,164
    Operating Expenses Qtr Cr 2,0221,6901,6461,6171,812
    Operating Profit Qtr Cr 530268266132351
    Depreciation Qtr Cr 196186185174184
    Interest Qtr Cr 114106110119104
    Tax Qtr Cr 126935-945
    Net Profit Qtr Cr 101105-9950
    Sign Up to Know More
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 8,3477,307
    Operating Expenses Annual Cr 6,9756,453
    Operating Profit Annual in Cr 1,196628
    Depreciation Cr 741677
    Interest Annual Cr 448344
    Tax Annual Cr 16166
    Net Profit Annual Cr 18-186
    Sign Up to Know More
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 1,005484
    Cash from Investing Activity Annual Cr -434-1,339
    Cash from Financing Annual Activity Cr -422818
    Net Cash Flow Annual Cr 148-37
    Sign Up to Know More
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 7,9116,774
    Fixed Assets Annual Cr 7,6067,780
    Total Non Current Assets Annual Cr 9,8479,687
    Total Current Assets Annual Cr 5,4644,835
    Total Assets Annual Cr 15,31214,523
    Sign Up to Know More
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 6057
    ROE Annual % 0-3
    ROCE Annual % 62
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 1712
    Sign Up to Know More
    Invest in Piramal Pharma

    Piramal Pharma Technicals

    EMA & SMA

    Current Price
    ₹150.3
    +0.45 (0.3%)
    pointer
    • Bullish Moving Average
    • ___
    • 14
    • Bearish Moving Average
    • ___
    • 2
    • 20 Day
    • ₹146.85
    • 50 Day
    • ₹140.86
    • 100 Day
    • ₹134.91
    • 200 Day
    • ₹126.17
    • 20 Day
    • ₹146.85
    • 50 Day
    • ₹136.38
    • 100 Day
    • ₹137.46
    • 200 Day
    • ₹122.42

    Piramal Pharma Resistance and Support

    PIVOT
    ₹150.17
    Resistance
    First Resistance 151.18
    Second Resistance 152.52
    Third Resistance 153.53
    RSI 56.94
    MFI 78.36
    MACD Single Line 4.16
    MACD 3.72
    Support
    First Support 148.83
    Second Support 147.82
    Third Supoort 146.48

    Piramal Pharma Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 3,769,267 181,339,435 48.11
    Week 16,138,451 450,746,925 27.93
    1 Month 8,794,859 281,699,334 32.03
    6 Month 6,587,505 290,838,363 44.15

    Piramal Pharma Result Highlights

    Piramal Pharma Synopsis

    NSE-Medical-Diversified

    Piramal Pharma is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 4390.11 Cr. and Equity Capital is Rs. 1322.95 Cr. for the Year ended 31/03/2024. Piramal Pharma Ltd. is a Public Limited Listed company incorporated on 04/03/2020 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is U24297MH2020PLC338592 and registration number is 338592.
    Market Cap 19,826
    Sales 4,390
    Shares in Float 86.00
    No of funds 215
    Yield 0.07
    Book Value 2.96
    U/D Vol ratio 2.6
    LTDebt / Equity 5
    Alpha 0.18
    Beta 1.18

    Piramal Pharma Shareholding Pattern

    Owner NameMar-24Dec-23Sep-23
    Promoters 35.02%35.02%35.02%
    Mutual Funds 9.01%6.28%3.8%
    Insurance Companies 2.64%2.88%3.8%
    Foreign Portfolio Investors 12.54%14.47%14.33%
    Financial Institutions/ Banks
    Individual Investors 15.13%15.57%16.95%
    Others 25.66%25.78%26.1%

    Piramal Pharma Management

    Name Designation
    Mrs. Nandini Piramal Chairperson
    Mr. Peter DeYoung Executive Director
    Mr. Vivek Valsaraj Executive Director & CFO
    Mr. Neeraj Bharadwaj Non Executive Director
    Mr. Nathalie Leitch Non Executive Director
    Mr. S Ramadorai Independent Director
    Mr. Jairaj Purandare Independent Director
    Mr. Peter Stevenson Independent Director
    Mr. Sridhar Gorthi Independent Director
    Ms. Vibha Paul Rishi Independent Director

    Piramal Pharma Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Piramal Pharma Corporate Action

    Date Purpose Remarks
    2024-05-10 Audited Results & Final Dividend
    2024-01-30 Quarterly Results
    2023-10-27 Quarterly Results
    2023-08-03 Quarterly Results
    2023-05-24 Audited Results

    Piramal Pharma MF Shareholding

    Name Amount(cr)
    HDFC Flexi Cap Fund Growth 52,874
    ICICI Prudential Value Discovery Fund Growth 42,664
    ICICI Prudential Equity & Debt Fund Growth 34,733
    HDFC Focused 30 Fund Growth 11,247
    Canara Robeco Equity Hybrid Fund Growth 10,077

    Piramal Pharma FAQs

    What is Share Price of Piramal Pharma ?

    Piramal Pharma share price is ₹150 As on 18 May, 2024 | 11:08

    What is the Market Cap of Piramal Pharma ?

    The Market Cap of Piramal Pharma is ₹19885.1 Cr As on 18 May, 2024 | 11:08

    What is the P/E ratio of Piramal Pharma ?

    The P/E ratio of Piramal Pharma is 1115.9 As on 18 May, 2024 | 11:08

    What is the PB ratio of Piramal Pharma ?

    The PB ratio of Piramal Pharma is 2.5 As on 18 May, 2024 | 11:08

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

    Email: support@5paisa.com

    Support Desk Helpline: 8976689766

    ©2024, 5Paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.